ClinicalTrials.gg
Active, not recruitingNCT07119125Updated Jun 4, 2026

A First-in-human, 3-part Study of MRT-8102 in Healthy Participants and Participants at Cardiovascular Risk With Elevated CRP

A Phase 1 interventional study of MRT-8102 and Placebo in Healthy Volunteers and Elevated CRP, sponsored by Monte Rosa Therapeutics, Inc. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-04.

Sponsored by Monte Rosa Therapeutics, Inc · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The principal aim of this study is to obtain safety and tolerability data when MRT-8102 is administered orally as single and multiple doses to healthy participants and participants at cardiovascular risk with elevated CRP. This information, together with the pharmacokinetic (PK) data, will help establish the dose and dosing regimen suitable for future studies.

The study drug, MRT-8102, is experimental. This is the first study in which MRT-8102 will be given to humans.

Part 1: Healthy participants will receive a single oral dose of MRT-8102 or placebo on Day 1

Part 2: Healthy participants will receive multiple oral doses of MRT-8102 or placebo for 7 consecutive days

Part 3: Participants at cardiovascular risk with elevated CRP will receive multiple oral doses of MRT-8102 or placebo for 28 consecutive days

Read the detailed description

The purpose of this study is to:

  • Learn about the safety and tolerability of single and multiple ascending oral doses of MRT-8102 in healthy adult participants
  • Learn about the safety and tolerability of 28-day daily dosing of MRT-8102 in participants at cardiovascular risk with elevated CRP
02

Conditions studied

  • Healthy Volunteers
  • Elevated CRP

Keywords

  • MRT-8102
  • MRT-8102-001
  • MRT
  • Monte Rosa Therapeutics
  • Healthy Volunteers
  • Single Ascending Dose
  • Multiple Ascending Dose
  • SAD
  • MAD
  • CRP
  • Cardiovascular Risk
03

In context

Lead sponsor

Monte Rosa Therapeutics, Inc is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Eligibility Criteria:

Inclusion criteria

Inclusion Criteria (all parts)

  • Healthy, adult, male or females 18-65 years of age
  • Non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to start of study
  • Able to swallow oral medications
  • Abstain from caffeine- and methylxanthine-containing beverages or food

Parts 3: Inclusion Criteria

  • Elevated CRP value ≥3.0 mg/L at the time of screening
  • Evidence of cardiovascular risk factors
  • No signs or symptoms of acute disease
  • No finding of clinical significance

Exclusion criteria

Exclusion Criteria (All Parts)

  • History or presence of medical or psychiatric condition or disease
  • Underwent surgical intervention or an operation withing 6 weeks prior to start of study
  • Has active TB, latent TB, a history of TB, or had close contact with a person with active TB within 8 weeks prior to the first dosing
  • Pregnant, breastfeeding, or planning a pregnancy or fathering a child during the study or within 3 months after the last study drug administration.
  • Positive urine drug or alcohol screen results
  • Positive results for (HIV), or virus or history of resolved hepatitis
  • Participation in another clinical study within 30 days or within 5 half-live (if known) prior to start of study
  • Currently receiving other immunomodulators
  • History of immunodeficiency, chronic inflammatory and chronic inflammation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Part 1: Single Ascending Dose (MRT-8102)

    Single Dose of MRT-8102

    Drug: MRT-8102

  • Placebo comparator
    Part 1: Single Ascending Dose (Placebo)

    Single Dose of Placebo

    Drug: Placebo

  • Experimental
    Part 2: Multiple Ascending Dose (MRT-8102)

    7-day Daily Dose of MRT-8102

    Drug: MRT-8102

  • Placebo comparator
    Part 2: Multiple Ascending Dose (Placebo)

    7-day Daily Dose of Placebo

    Drug: Placebo

  • Experimental
    Part 3: elevated CRP (MRT-8102)

    28-day Daily Dose of MRT-8102

    Drug: MRT-8102

  • Placebo comparator
    Part 3: elevated CRP (Placebo)

    28-day Daily Dose of Placebo

    Drug: Placebo

Interventions

  • DrugMRT-8102

    Oral capsules

  • DrugPlacebo

    Oral capsules

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of single doses of MRT-8102 in healthy adult participants

    Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs

    Time frame: 15 days

  2. To evaluate the safety and tolerability of multiple ascending doses of MRT-8102 in healthy adult participants.

    Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs

    Time frame: 21 days

  3. To evaluate the safety and tolerability of 28-day daily dosing of MRT-8102 in participants at cardiovascular risk with elevated CRP

    Incidence of treatment-emergent adverse events by type severity seriousness and relationship to treatment and changes from baseline in safety-related clinical lab parameter, vital signs 12-lead ECGs and PEs

    Time frame: 56 days

Secondary outcomes

  1. Characterize the PK Profile (peak plasma concentration) of MRT-8102 after single doses of MRT-8102 in healthy adult participants

    Peak plasma Concentration (Cmax)

    Time frame: Up to 8 days

  2. Characterize the PK Profile (plasma concentration versus time) of MRT-8102 after single doses of MRT-8102 in healthy adult participants

    Area under the plasma concentration versus time (AUC)

    Time frame: Up to 8 days

  3. Assess the effect of a high-fat/high-calorie meal on the PK (peak plasma concentration) of MRT-8102 02 in healthy adult participants

    Peak plasma Concentration (Cmax) - comparing fasted vs fed

    Time frame: Up to 8 days

  4. Assess the effect of a high-fat/high-calorie meal on the PK (plasma concentration versus time) of MRT-8102 02 in healthy adult participants

    Area under the plasma concentration versus time (AUC) - comparing fasted vs fed

    Time frame: Up to 8 days

  5. Characterize the PK profile (peak plasma concentration) of MRT-8102 in plasma after multiple doses of MRT-8102 in healthy adult participants

    Peak plasma Concentration (Cmax)

    Time frame: Up to 14 days

  6. Characterize the PK profile (plasma concentration versus time) of MRT-8102 in plasma after multiple doses of MRT-8102 in healthy adult participants

    Area under the plasma concentration versus time (AUC)

    Time frame: Up to 14 days

  7. Characterize the PK Profile (peak plasma concentration) of MRT-8102 when administered daily to participants at cardiovascular risk with elevated CRP

    Peak plasma Concentration (Cmax)

    Time frame: Up to 35 days

  8. Characterize the PK Profile (plasma concentration versus time) of MRT-8102 when administered daily to participants at cardiovascular risk with elevated CRP

    Area under the plasma concentration versus time (AUC)

    Time frame: Up to 35 days

  9. Assess the impact of MRT-8102 on serum concentration of CRP

    Mean changes from pre-dose baseline in serum CRP levels.

    Time frame: Up to 35 days

07

Study locations

4 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jul 2026, 13 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2025
First posted
Aug 12, 2025
StartActual
Jun 27, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2026
Last update
Jun 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07119125
Lead sponsor
Monte Rosa Therapeutics, Inc
Responsible party
Sponsor
First posted
Aug 12, 2025
Start date
Jun 27, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 2026 (estimated)
Last update
Jun 4, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion